Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study

This publication has 16 references indexed in Scilit:

• Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule
  Journal of Clinical Oncology, 1999
• Cancer statistics, 1998
  CA: A Cancer Journal for Clinicians, 1998
• Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
  Journal of Clinical Oncology, 1997
• Future directions in the management of small cell lung cancer
  Lung Cancer, 1994
• Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro
  British Journal of Cancer, 1994
• Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1991
• Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study
  Cancer, 1990
• Identification of new drugs in pretreated patients with small cell lung cancer
  European Journal of Cancer and Clinical Oncology, 1989
• The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancer
  European Journal of Cancer and Clinical Oncology, 1988
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958